Related Experiment Video
Updated: Dec 26, 2025

06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
584
[Appendix Cancer with Long-Term Survival after Multimodality Therapy-A Case Report]
Dai Kitagawa1, Qingjiang Hu, Kazuki Takada
1Dept. of Surgery, Saiseikai Yahata General Hospital.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|March 12, 2020
Summary
This case study highlights a 65-year-old woman
Area of Science:
- Oncology
- Gastroenterology
- Surgical Oncology
Background:
- Appendix cancer, a rare malignancy, often presents with a poorer prognosis than colorectal cancer due to frequent metastatic spread.
- Mucinous cystadenocarcinoma of the appendix requires specific management strategies.
- This report details a unique case of recurrent appendix cancer with extensive metastases.
Observation:
- A 65-year-old woman was diagnosed with Stage I appendix cancer (mucinous cystadenocarcinoma) in 2002.
- She developed ovarian metastases in 2006 and disseminated recurrence in 2011, treated with chemotherapy and surgery.
- Elevated serum CEA levels in 2016 preceded the identification of a liver tumor in 2017, leading to diaphragm resection.
Findings:
- The patient achieved long-term survival exceeding 17 years despite multiple recurrences and disseminated disease.
- Multimodality therapy, including systemic chemotherapy (bevacizumab plus mFOLFOX6) and aggressive surgical interventions, was crucial.
- Persistent follow-up and timely, aggressive treatment were key to managing this complex case.
Implications:
- This case demonstrates the possibility of long-term survival in advanced appendix cancer with comprehensive treatment approaches.
- It underscores the importance of vigilant monitoring for recurrence, even with normal imaging findings, by tracking tumor markers like CEA.
- Aggressive surgical resection and multimodal therapy can significantly improve outcomes for patients with recurrent and metastatic appendix mucinous cystadenocarcinoma.
More Related Videos
Related Concept Videos
Cancer Survival Analysis
592
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
592
Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K

